TG Therapeutics, Inc. TGTX
5 targets with a reported result
Releases of the last 3 yearsThe numbers TGTX said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $825.00M to $850.00M release Feb 26, 2026
Raised $885.00M to $900.00M release May 6, 2026
Raised $890.00M to $905.00M release Aug 3, 2026
Raised $1.00B release Nov 9, 2026
|
– | Not reported yet | |
The company's words2026 Financial Guidance … million, including BRIUMVI U.S. net product revenue of approximately $825-$850 million release Feb 26, 2026 Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026 BRIUMVI U.S. net product revenue target to $885-900 million release May 6, 2026 Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million release Aug 3, 2026 TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full- Year Revenue Guidance Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million release Nov 9, 2026 | ||||
| Revenue Q2 of fiscal 2026 |
Given $220.00M release May 6, 2026
|
$240.34M 10-Q filed 2026-08-05 |
Above the range | |
The company's words2026 Financial Guidance … Provides second quarter 2026 target BRIUMVI U.S. net product revenue of approximately $220 million release May 6, 2026 | ||||
| Revenue Q1 of fiscal 2026 |
Given $185.00M to $190.00M release Feb 26, 2026
|
$204.92M 10-Q filed 2026-05-06 |
Above the range | |
The company's wordsQ1 2026 target BRIUMVI U.S. net product revenue of approximately $185-$190 million Full year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 million excluding non-cash compensation, in addition release Feb 26, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $540.00M release Mar 3, 2025
Raised $570.00M to $575.00M release Aug 4, 2025
Raised $600.00M release Nov 3, 2025
|
$616.29M 10-K filed 2026-02-27 |
Above the range | |
The company's words2025 Financial Guidance … Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million release Mar 3, 2025 Raises BRIUMVI U.S. net product revenue target to $570 - $575 million for the full year 2025 (prior guidance of $560 million for full year 2025) release Aug 4, 2025 2025 Financial Guidance … Raises total global revenue target to approximately $600 million for the full year 2025 (prior guidance of $585 million for full year 2025) release Nov 3, 2025 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $220.00M to $260.00M release Feb 28, 2024
Raised $290.00M to $300.00M release Aug 6, 2024
Raised $300.00M to $305.00M release Nov 4, 2024
|
$329.00M 10-K filed 2025-03-03 |
Above the range | |
The company's wordsBRIUMVI U.S. net product revenue target of approximately $220 million to $260 million for the full year 2024 release Feb 28, 2024 Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million release Aug 6, 2024 Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million release Nov 4, 2024 | ||||
| Revenue Q2 of fiscal 2024 |
Given $65.00M release May 1, 2024
|
$73.47M 10-Q filed 2024-08-09 |
Above the range | |
The company's words2024 Updated Target U.S. BRIUMVI Guidance … Q2 2024 target BRIUMVI U.S. net product revenue of approximately $65 million release May 1, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-28), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TGTX/export.csv") into a cell.